Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Intermountain Healthcare, a Utah-based, nonprofit healthcare system, which leverages genomic testing and data analytics to advance research intended to improve outcomes for cancer patients.
Intermountain Healthcare is leveraging Tempus’ solid tumor/normal genomic test, xT, to generate whole transcriptomic data on existing samples for research purposes. Tempus performs high-quality, whole transcriptome RNA sequencing with validated fusion detection to provide deeper molecular profiling that supplements DNA data. Intermountain plans to use the matched RNA and DNA data to further its oncology research intended to advance patient care and outcomes. Additionally, Tempus is structuring and harmonizing Intermountain’s de-identified clinical and molecular datasets to increase accessibility for researchers and further enhance Intermountain’s research initiatives.
“We believe that RNA has the power to unlock insights that can transform patient care in a way that DNA cannot do on its own,” said Joel Dudley, Chief Scientific Officer of Tempus. “Intermountain delivers personalized treatment for so many cancer patients, and we look forward to working together to help advance its research efforts.”
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.